EUCTR2011-005307-33-IT进行中（未招募）不适用
Exploratory study of L.S.E.S.r. (PERMIXON 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH; a multinational, multicentric, randomised, double blind parallel-group prospective study.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Male patient - Between 45 and 85 years old. - Patient with bothersome lower urinary tract symptoms such as pollakiuria (daytime or night time), urgency, sensation of incomplete voiding, delayed urination or weak stream, existing for over 12 months - I-PSS = 10 at selection visit and = 12 at randomisation visit (visit 2) - Stable patient's disease at randomisation defined as an absolute difference of 2 or less on I-PSS between selection and randomisation visits (visit 1 and visit 2) - I-PSS QoL score = 3 evaluated at selection and randomisation visits, - 5 mL/s = maximum urinary flow rate < 15 mL/s for a voided volume = 150 mL and = 500 mL evaluated at randomisation visit (2 measurements if necessary) - Prostatic volume =30 cm³ determined by transrectal ultrasound at randomisation visit (visit 2) - Serum total PSA at randomisation visit (visit 2) : a) = 4 ng/mL b) = 10 ng/mL and PSA (free) / PSA (total) = 25% or negative prostate biopsy within the past 6 months prior to selection visit. Ethical /legal considerations: - Patient able to understand and sign the informed consent and understand and fill in self-questionnaires - Having signed his written informed consent - Affiliated to a social security system, or is a beneficiary (if applicable in thenational regulation).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •- Post-void residual urine volume > 200 mL (by suprapubic ultrasound) at randomisation visit (visit 2). - Urological history : Urethral stricture disease and/or bladder neck disease Active (at selection and randomisation visits) or recent (< 3 months) or recurrent urinary tract infection Urinary retention with indwelling catheter or intermittent catheterisation History of unprompted acute urinary retention in the past Indication of BPH surgery Stone in bladder or urethra Acute or chronic (documented) prostatitis Prostate cancer treated or untreated Bladder cancer Interstitial cystitis (documented by symptoms and/or biopsy) Active upper tract stone disease causing symptoms - Patient with history of surgery of the prostate, bladder neck or pelvic region - Any local and/or systemic inflammation disorders at selection and randomisation visit - Any neurologic or psychiatric disease/disorder interfering with detrusor or sphincter muscle - Insulin-dependent diabetes mellitus and non-controlled non insulindependent diabetes mellitus - Chronic renal insufficiency, with serum creatinine = 30 % above the upper normal range at randomisation visit (visit 2) - History of severe hepatic failure - Orthostatic hypotension defined as a decrease of at least 20 mmHg in SBP or 10 mmHg in DBP between supine and 2-minute standing positions at selection (visit 1) and randomisation visit (visit 2) - Patient with any severe underlying disease considered as life threatening in the short or medium term - Known hypersensitivity to one of the constituents of the study drugs - Concomitant medication with at selection visit (visit 1) and randomisation visit (visit 2) : Anti-androgens (must be discontinued at least 6 months prior to selection) LH-RH analogues (must be discontinued at least 6 months prior to selection) 5 alpha-reductase inhibitors (must be discontinued at least 3 months prior to selection) Plants extracts used for treatment of LUTS (must be discontinued at least 3 months prior to selection) Alpha blockers and alpha/beta blockers (must be discontinued at least 1 month prior to selection) ACE inhibitors, calcium antagonists, beta blockers or diuretics (except if stable dose and initiated more than 6 weeks prior to selection) NSAIDs by systemic route (except aspirin up to 325 mg/day for cardiovascular prophylaxis) Corticosteroids by systemic route. Antibiotics by systemic route Sympathomimetics, antihistamines, antidepressants (anticholinergic), atropine, antispasmodic drugs, antiparkinsonism drugs, pseudoephedrine, chlorpheniramine, spironolactone, mepartricine - Patient with a history of drug or alcohol abuse
研究者
相似试验
进行中（未招募）
不适用
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH.The aim of the proposed study is to assess the activity on inflammation biomarkers of L.S.E.S.r (PERMIXON® 160mg hard capsule) and Tamsulosine LP in the treatment of BPH. The potential links between serum and urinary markers of inflammation and BPH clinical symptoms at baseline and on treatment will be explored.MedDRA version: 14.1Level: LLTClassification code 10004447Term: Benign prostatic hypertrophySystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-005307-33-PTPIERRE FABRE MEDICAMENT200
进行中（未招募）
不适用
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPHEUCTR2011-005307-33-ESPIERRE FABRE MEDICAMENT
进行中（未招募）
不适用
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicentric, randomised, double-blind, parallel-group prospective studyThe aim of the proposed study is to assess the activity on inflammation biomarkers of L.S.E.S.r (PERMIXON® 160mg hard capsule) and Tamsulosine LP in the treatment of BPH. The potential links between serum and urinary markers of inflammation and BPH clinical symptoms at baseline and on treatment will be explored.MedDRA version: 14.1Level: LLTClassification code 10004447Term: Benign prostatic hypertrophySystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-005307-33-FRPIERRE FABRE MEDICAMENT
已完成
4 期
PERmixon® in LUTS Evaluation Study (PERLES)Benign Prostatic Hyperplasia (BPH)NCT02121613Pierre Fabre Medicament833
招募中
不适用
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-TrialRadiation NephropathyMetastatic Castrate Resistant Prostate Cancer (mCRPC)Kidney DiseaseNCT06720532Hannah Schaefer100